PolyPeptide Group AG (0AAJ.L)

29.65 -0.72 (-2.36%) At close: 04:19PM BST

PolyPeptide Group AG

Neuhofstrasse 24
Baar 6340
Switzerland
41 435 020 580
https://www.polypeptide.com

Sector(s): 
Industry: 
Full-time employees: 1,273

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Klaus Peter Wilden	Executive Chair	305.77k	N/A	1957
Mr. Juan Jose Gonzalez	Chief Executive Officer	1.17M	N/A	1972
Mr. Marc Augustin	Chief Financial Officer	N/A	N/A	1972
Mr. Jens Fricke	Director of Global Operations	N/A	N/A	1965
Rene Vestergaard	Director of Corporate Finance	N/A	N/A	N/A
Mr. Olivier Ludemann-Hombourger	Director Global Innovation & Technology	N/A	N/A	1972
Ms. Christina Del Vecchio	General Counsel & Corporate Secretary	N/A	N/A	1978
Mr. Neil James Thompson	Director of Global Sales & Marketing	N/A	N/A	1972
Ms. Monika Casanova	Chief Human Resources Officer	N/A	N/A	1979
Christophe Chevalier	Head of Technical Department - Braine	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Corporate governance

PolyPeptide Group AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.